Is Surgery Essential in Kidney Cancer? Ablation Keeps Pace with Surgery
In this article
A 10-Year National Follow-Up of Kidney Tumours: Ablation Keeps Pace with Surgery
The long-standing view in oncology that “surgery is the gold standard for kidney tumours” is being challenged by a large national cohort study published in Radiology . Follow-up data covering 1901 patients over more than 10 years demonstrated that, for kidney tumours smaller than 4 cm (T1a), image-guided thermal ablationdid not differ statistically from surgery (partial nephrectomy) in terms of cancer-specific survival and metastasis control. Furthermore, ablation allows patients to be discharged on the same day.
A 10-Year Statistical Comparison
The study conducted by Ahrenfeldt and colleagues established the long-term oncologic safety of ablation with clear figures:
Ablation Versus Surgery: Oncologic Balance
The study's most striking finding is that the difference in metastatic risk between invasive surgery and minimally invasive ablation is not meaningful in practice:
| Parameter | Thermal Ablation (n=1122) | Partial Nephrectomy (n=779) |
|---|---|---|
| Local Recurrence Rate | 2.41% | 1.20% |
| Distant Metastasis Rate | 1.67% | 4.38% |
| Cancer-Specific Survival | 94% | 96% |
| Complications (Clavien-Dindo 3+) | Lower | Higher |
Procedure: Minimally Invasive Thermal Destruction
The techniques used in the study were radiofrequency ablation (RFA) or cryoablation (freezing), depending on the patient's anatomy:
🎓 DROZDOGAN Academy — Article Analysis
RADIOLOGY 2026 IN DEPTH · AHRENFELDT ET AL. STUDY
Recurrence Is No Longer a Barrier
According to Ahrenfeldt's data, the recurrence rate after ablation is only slightly higher than after surgery (2.4% vs 1.2%). However, this difference is not reflected in survival rates. The reason is that tumours recurring after ablation can be successfully treated with repeat ablation or salvage surgery.
The Advantage in Age and Comorbidity
Patients in the ablation group of the Danish cohort were generally older and had comorbidities. Despite this, their lower metastasis rates compared with the surgical group (1.67% vs 4.38%) underscore the method's systemic oncologic success.
Conclusion
The 2026 Radiology study has opened the door to a “modern era” in which thermal ablation may replace surgery for T1a kidney cancers. Reducing hospital stay to 0 days, competing with surgery in metastasis control and preserving kidney function, ablation is now among the options that can be considered first-line treatment, particularly for older patients, those at high surgical risk or individuals with a solitary kidney.
References
- Ahrenfeldt J, Lyskjær I, et al. "Thermal Ablation versus Partial Nephrectomy for T1a Renal Cell Carcinoma: A 10-Year National Cohort Study." Radiology. 2026 March; Vol. 318(3). doi:10.1148/radiol.2026a1000.
- RSNA (Radiological Society of North America) Press Release. "New Data Confirms Safety of Kidney Ablation over 10 Years." March 2026.
This technical summary was prepared for medical information purposes on the basis of the original scientific study data published in Radiology (2026).
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.